ReviewExpert opinion on therapeutic patents2017
Recent trends in neuropathic pain patents.
Review in Expert opinion on therapeutic patents, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Notch signaling pathway: a new target for neuropathic pain therapy.The journal of headache and pain · 2023Review
- Neuropathic pain in leprosy: symptom profile characterization and comparison with neuropathic pain of other etiologies.Pain reports · 2018Article
- Highly selective A3 adenosine receptor agonists relieve chronic neuropathic pain.Expert opinion on therapeutic patents · 2017Article
Corrections and comments
- Commented on by
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionNeuropathic pain (NP) is one of the most important health problems faced nowadays. NP is a chronic disease that cannot be treated like other pain conditions because it is developed from a nerve injury that evolves into a permanent dysfunction of the central and/or peripheral nervous system. Therefore, it involves the participation of several systems and should be viewed as a multi-factorial disease that needs a whole new pharmacological strategy in order to achieve the desired pain relief. Areas covered: The Espacenet site was used as the main source in order to perform the patent research for NP treatment. This review covers the patents with relevant approaches for NP treatment from 2014 until today. Expert opinion: Our patent research has shown that there is not a consensus approach to treat NP in any of its forms. In our opinion, the approach regarding NP needs to be like cancer's approach. As there are different types of cancer and different ways to treat them, the same needs to be done for NP. Currently, there are several promising targets, which corroborates that this is a wide-open research area. For these reasons, neuropathic pain is a therapeutic field full of potential for innovation.
Indexed as
Identifiers
27998196What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.